
    
      This is a 26 week, multiregional, open-label extension study designed to evaluate the
      long-term safety and tolerability of SEP-363856 for the treatment of subjects with
      schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

      No statistical hypothesis tests will be performed.
    
  